Storia in 18 fonti

Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity

A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As Healio previously reported, retatrutide (Eli Lilly), an injectable GIP/GLP-1/glucagon receptor agonist under investigation for the treatment of obesity, type 2 diabetes and other cardio-renal-metabolic disorders, was

Raccontata da

thehindubusinessline.com

scientificamerican.com

washingtonexaminer.com

time.com+6 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo3 mesi fa

Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity

originale

Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity

Confronto fonti

Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity

Timeline cronologica

Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity

People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)

Eli Lilly retatrutide Phase 3 obesity trial results 2026

Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight

A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says

Lilly’s triple agonist still leads among late-stage obesity assets

Eli Lilly retatrutide Phase 3 obesity trial results 2026

Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight

New weight-loss shot more powerful than old GLP-1s, Eli Lilly says

Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results

Eli Lilly diz que novo medicamento ajuda pacientes com obesidade a perder 28% do peso corporal

Super Ozempic? New weight-loss drug sees even better results in recent study

Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight

New Eli Lilly weight loss drug has dramatic effects in clinical trial

A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)

Some people are losing too much weight in Retatrutide trial.

Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com

La retatrutida de Eli Lilly reduce la obesidad en un 30% a los dos a�os de tratamiento

Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1